Skip to content
Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Wesana Health Commences Trading on the CSE

Wesana Health Commences Trading on the CSE

  • Post published:May 10, 2021
  • Post category:Press Release
Read more about the article Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

  • Post published:May 10, 2021
  • Post category:Press Release
Read more about the article Psychedelic Research Bulletin: April 2021

Psychedelic Research Bulletin: April 2021

  • Post published:May 9, 2021
  • Post category:Psychedelics Research Review
Read more about the article Psychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain; the Proliferation of Deuteration

Psychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain; the Proliferation of Deuteration

  • Post published:May 8, 2021
  • Post category:Psychedelic Bulletin
Read more about the article Small Pharma Provides Update to Patent Portfolio Including Receipt of an in Order for Grant Notice for its Patent Related to Psychedelic Tryptamines

Small Pharma Provides Update to Patent Portfolio Including Receipt of an in Order for Grant Notice for its Patent Related to Psychedelic Tryptamines

  • Post published:May 7, 2021
  • Post category:Press Release
Read more about the article Gilgamesh Pharmaceuticals Closes On $27 Million Series A Round

Gilgamesh Pharmaceuticals Closes On $27 Million Series A Round

  • Post published:May 6, 2021
  • Post category:Press Release
Read more about the article Field Trip Health Ltd. Announces DTC Eligibility

Field Trip Health Ltd. Announces DTC Eligibility

  • Post published:May 6, 2021
  • Post category:Press Release
Read more about the article Nova Mentis Launches Autism Clinical Study

Nova Mentis Launches Autism Clinical Study

  • Post published:May 6, 2021
  • Post category:Press Release
Read more about the article Braxia Scientific Introduces “Braxia Health” a Growing Network of Clinics Leading Novel Psychedelic Research and Treatments for Mental Disorders

Braxia Scientific Introduces “Braxia Health” a Growing Network of Clinics Leading Novel Psychedelic Research and Treatments for Mental Disorders

  • Post published:May 5, 2021
  • Post category:Press Release
Read more about the article Entheon Biomedical Lists on OTCQB Venture Market

Entheon Biomedical Lists on OTCQB Venture Market

  • Post published:May 5, 2021
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2026, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More